JP2023541670A5 - - Google Patents

Info

Publication number
JP2023541670A5
JP2023541670A5 JP2023517698A JP2023517698A JP2023541670A5 JP 2023541670 A5 JP2023541670 A5 JP 2023541670A5 JP 2023517698 A JP2023517698 A JP 2023517698A JP 2023517698 A JP2023517698 A JP 2023517698A JP 2023541670 A5 JP2023541670 A5 JP 2023541670A5
Authority
JP
Japan
Prior art keywords
seq
polypeptide
immunotherapy composition
peptide
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023517698A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023541670A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/045058 external-priority patent/WO2022060488A1/en
Publication of JP2023541670A publication Critical patent/JP2023541670A/ja
Publication of JP2023541670A5 publication Critical patent/JP2023541670A5/ja
Pending legal-status Critical Current

Links

JP2023517698A 2020-09-18 2021-08-06 アルツハイマー病の処置のためのマルチエピトープワクチン Pending JP2023541670A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063080619P 2020-09-18 2020-09-18
US63/080,619 2020-09-18
PCT/US2021/045058 WO2022060488A1 (en) 2020-09-18 2021-08-06 Multiepitope vaccine for the treatment of alzheimer's disease

Publications (2)

Publication Number Publication Date
JP2023541670A JP2023541670A (ja) 2023-10-03
JP2023541670A5 true JP2023541670A5 (enExample) 2025-08-19

Family

ID=80777125

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023517698A Pending JP2023541670A (ja) 2020-09-18 2021-08-06 アルツハイマー病の処置のためのマルチエピトープワクチン

Country Status (12)

Country Link
US (1) US20230355729A1 (enExample)
EP (1) EP4213941A4 (enExample)
JP (1) JP2023541670A (enExample)
KR (1) KR20230087499A (enExample)
CN (1) CN116438191A (enExample)
AR (1) AR123187A1 (enExample)
AU (1) AU2021345483A1 (enExample)
CA (1) CA3192387A1 (enExample)
IL (1) IL301262A (enExample)
MX (1) MX2023003008A (enExample)
TW (1) TW202227464A (enExample)
WO (1) WO2022060488A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
WO2020160156A2 (en) 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
JP2025507875A (ja) 2022-02-28 2025-03-21 トライデム バイオサイエンス ゲーエムベーハー ウント コンパニー カーゲー 少なくともβ－グルカン若しくはマンナンからなるか、又はこれを含む結合体
EP4486389A1 (en) 2022-02-28 2025-01-08 Tridem Bioscience GmbH & Co KG A conjugate comprising at least a beta-glucan

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69637571D1 (de) * 1995-10-20 2008-08-07 Univ Nebraska Zusammensetzung und verfahren zur verstärkung der immunantwort antigen-präsentierender zellen
US6632934B1 (en) * 1998-09-30 2003-10-14 Board Of Regents, The University Of Texas System MORC gene compositions and methods of use
EP2887955B1 (en) * 2012-08-21 2020-08-19 Institute for Molecular Medicine, Inc. Compositions and methods related to diseases associated with deposits of amyloid, tau, and alpha-synuclein
UA118441C2 (uk) * 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
CA2944402A1 (en) * 2014-04-08 2015-10-15 Prothena Biosciences Limited Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
US10745456B2 (en) * 2015-04-01 2020-08-18 The Scripps Research Institute Methods and compositions related to GPCR agonist polypeptides
WO2021135664A1 (zh) * 2019-12-30 2021-07-08 江苏集萃智能液晶科技有限公司 温敏显色的液晶微胶囊及其制备方法和温敏显色的容器
BR112022023366A2 (pt) * 2020-05-19 2023-05-02 Othair Prothena Ltd Vacina com múltiplos epítopos para o tratamento de mal de alzheimer
WO2022032166A1 (en) * 2020-08-07 2022-02-10 Othair Prothena Limited Multiepitope vaccine for the treatment of alzheimer's disease

Similar Documents

Publication Publication Date Title
JP2023526500A5 (enExample)
JP2023541670A5 (enExample)
JP2023536995A5 (enExample)
Hamley Peptides for vaccine development
JP2023541669A5 (enExample)
TWI355390B (en) Immunogenic peptide carrier conjugates and methods
TWI379839B (en) Aβ immunogenic peptide carrier conjugates and methods of producing same
JP2023536746A5 (enExample)
RU2007145052A (ru) Композиции пептидного конъюгата и способы для профилактики и лечения болезни альцгеймера
CA2167730A1 (en) Synthetic multiple tandem repeat mucin and mucin-like peptides and uses thereof
US20090123488A1 (en) Compositions and methods for the treatment and prophylaxis of Alzheimer's disease
HUE031924T2 (en) Peptides, conjugates and method for increasing immunogenicity of a vaccine
JP2023541671A5 (enExample)
JP2012523379A (ja) 免疫原性組成物およびその使用
US20030175285A1 (en) Molecule of pharmaceutical interest comprising at its n-terminal a glutamic acid or a glutamine in the form of a physiologically acceptable strong acid
TW202212348A (zh) 用於治療阿茲海默症之β類澱粉蛋白疫苗
JP6352251B2 (ja) Ｃｒｍ１９７担体タンパク質に結合したｈｉｖｇｐ４１ペプチドを含む免疫原性化合物
JP2023541670A (ja) アルツハイマー病の処置のためのマルチエピトープワクチン
US20220362159A1 (en) Tabletization of peptide self-assemblies and methods of making and using the same
US20050049197A1 (en) Induction of immune response against desired determinants
CA2441809C (en) Liposomal vaccines comprising dilipopeptides for modulating t1 and t2 immune responses
JP2023541671A (ja) シヌクレイノパチーの処置のためのアルファ－シヌクレインワクチン
FR2776926A1 (fr) Lipopeptides inducteurs de cytotoxicite t lymphocytaire portant au moins un epitope t auxiliaire, et leurs utilisations pour la vaccination
Gras-Masse Single-chain lipopeptide vaccines for the induction of virus-specific cytotoxic T cell responses in randomly selected populations
Zeng et al. Lipidation of intact proteins produces highly immunogenic vaccine candidates